Catalog #CP109
RecombiMAb anti-mouse HER2 (domain I) (CD340)
Clone
H2Mab-304-CP109
Reactivities
Mouse
Applications
ELISA
Flow cytometry
For details on in vivo applications, please contact technicalservice@bioxcell.com
Flow cytometry
For details on in vivo applications, please contact technicalservice@bioxcell.com
Isotype
Mouse IgG2a, κ
(switched from Rat Ig1, κ)
(switched from Rat Ig1, κ)
You may also be interested in:
Product Description
The H2Mab-304-CP109 monoclonal antibody is a chimeric version of the original H2Mab-304 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG1, κ to Mouse IgG2a, κ. H2Mab-304-CP109 has an effector function competent Fc domain allowing for activation of Fcγ receptors (FcγRs) to trigger antibody‑dependent cellular cytotoxicity (ADCC), antibody‑dependent cellular phagocytosis (ADCP), complement‑dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. The mouse IgG2a isotype demonstrates strong effector functions due to potent interaction with mFcγRIV, which is functionally similar to the FcγRIIIa receptor involved in human ADCC. Species-matched chimeric antibodies result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
The H2Mab-304-CP109 monoclonal antibody reacts with domain I of mouse receptor tyrosine-protein kinase erbB-2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), CD340, or NEU. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. The HER2 receptor contains a cytoplasmic tyrosine kinase domain, multiple cytoplasmic tyrosine residues that function as phosphorylation sites, a hydrophobic single-pass transmembrane domain, and an extensive extracellular domain (ECD) subdivided into four functional domains (I, II, III, and IV). Domains I and III facilitate ligand binding, domain II reinforces protein-protein interactions during dimerization, and domain IV stabilizes interactions between HER2 and its dimerization partner. HER2 lacks identified ligands; nonetheless, its homodimerization (HER2/HER2) and heterodimerization (EGFR/HER2, HER2/HER3, and HER2/HER4) facilitate HER2 activation, subsequently modulating downstream signaling pathways, including PI3K/Akt/mTOR and NF-kB. HER2 is essential for cell proliferation, survival, and differentiation, and in cancers, dysregulated HER2 signaling or its overexpression often correlates with aggressive tumor growth. In addition to breast cancer, HER2 is overexpressed in gastric, gastroesophageal, colorectal, lung, endometrial, and ovarian cancers.
The H2Mab-304-CP109 monoclonal antibody reacts with domain I of mouse receptor tyrosine-protein kinase erbB-2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), CD340, or NEU. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. The HER2 receptor contains a cytoplasmic tyrosine kinase domain, multiple cytoplasmic tyrosine residues that function as phosphorylation sites, a hydrophobic single-pass transmembrane domain, and an extensive extracellular domain (ECD) subdivided into four functional domains (I, II, III, and IV). Domains I and III facilitate ligand binding, domain II reinforces protein-protein interactions during dimerization, and domain IV stabilizes interactions between HER2 and its dimerization partner. HER2 lacks identified ligands; nonetheless, its homodimerization (HER2/HER2) and heterodimerization (EGFR/HER2, HER2/HER3, and HER2/HER4) facilitate HER2 activation, subsequently modulating downstream signaling pathways, including PI3K/Akt/mTOR and NF-kB. HER2 is essential for cell proliferation, survival, and differentiation, and in cancers, dysregulated HER2 signaling or its overexpression often correlates with aggressive tumor growth. In addition to breast cancer, HER2 is overexpressed in gastric, gastroesophageal, colorectal, lung, endometrial, and ovarian cancers.
Specifications
| Isotype | Mouse IgG2a, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a isotype control, unknown specificity |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Mouse HER2-overexpressing LN229 cells |
| Reported Applications |
ELISA Flow cytometry For details on in vivo applications, please contact technicalservice@bioxcell.com |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein G |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |